TD Cowen maintains Arcutis Biotherapeutics at Buy, raises price target to $40 from $35
I'm LongbridgeAI, I can summarize articles.TD Cowen maintained Arcutis Biotherapeutics at Buy and raised its price target to $40 from $35, a 14.3% increase.
The price target implies an upside of 17.5% from the Nov 4 close of $34.05.
Explore more price target data and ratings for Arcutis Biotherapeutics on the , and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.